Fundraising Fox

Eikonoklastes Therapeutics

Cincinnati, US · 2 known investors

Biotech

Founders & leadership

TF
Thomas FinnNamed on SEC filing
JN
Joseph NolanNamed on SEC filing
RJ
Robert JohnsonNamed on SEC filing
SL
Samuel LeeNamed on SEC filing
BH
Bruce HalprynNamed on SEC filing
KM
Kenneth MorandNamed on SEC filing

Investors · 2

CincyTechCincinnati · $500K – $750K
JobsOhio VenturesColumbus

Reported raises · per SEC filings

Form D private placements
▶$13.6MraisedJul 2025 · 14 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Thomas FinnDirector
  • Joseph NolanDirector
  • Robert JohnsonDirector
  • Samuel LeeExecutive Officer, Director
  • Bruce HalprynExecutive Officer, Director
  • Kenneth MorandDirector
Offering amount
$15.8M
Amount sold
$13.6M
First sale
Jul 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.4MraisedJun 2024 · 3 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Thomas FinnDirector
  • Neel PatelDirector
  • Meyer FrucherDirector
  • Kenneth MorandDirector
  • Bruce HalprynExecutive Officer, Director
  • Samuel LeeExecutive Officer, Director
Offering amount
$8M
Amount sold
$2.4M
First sale
Jun 2024
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2MraisedNov 2023 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Samuel LeeExecutive Officer, Director
  • Neel PatelDirector
  • Bruce HalprynExecutive Officer, Director
  • Thomas FinnDirector
  • Kenneth MorandDirector
  • Meyer FrucherDirector
Offering amount
$15M
Amount sold
$2M
First sale
Nov 2023
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.8MraisedJan 2022 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Bruce HalprynExecutive Officer, Director
  • Kenneth MorandDirector
  • Thomas FinnDirector
  • Samuel LeeExecutive Officer, Director
  • Neel PatelDirector
Offering amount
$7M
Amount sold
$2.8M
First sale
Dec 2021
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.2MraisedMay 2021 · 9 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Bruce HalprynExecutive Officer, Director, Promoter
  • Thomas FinnDirector
  • Samuel LeeExecutive Officer, Director
  • Neel PatelDirector
  • Kenneth MorandDirector
Offering amount
$7M
Amount sold
$3.2M
First sale
Apr 2021
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.1MraisedMar 2020 · 2 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • SAMUEL LEEExecutive Officer, Director, Promoter
  • BRUCE HALPRYNExecutive Officer, Director, Promoter
Offering amount
$4M
Amount sold
$1.1M
First sale
Feb 2020
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Sell or Invest in Eikonoklastes Therapeutics Stock Pre-IPOnasdaqprivatemarket.com · Nov 2025Eikonoklastes Therapeutics has filed a notice of an exempt offering of securities to raise $15,764,780.00 in New Funding. - intelligence360intelligence360.news · Sep 2025CincyTech-backed Eikonoklastes Therapeutics gets FDA orphan drug designation for ALS treatment - Cincinnati Business Courierbizjournals.com · Nov 2022Eikonoklastes Closes Series A Fundingfinsmes.com · Jun 2021Eikonoklastes Closes Oversubscribed Series A Financing, Helping to Advance Immunotherapies Toward Clinical Trial Stagebusinesswire.com · Jun 2021Eikonoklastes Therapeutics Closes Oversubscribed Seed Financing to Advance Next-Generation Tissue Factor (TF) Immunotherapies With Initial Focus on Triple-Negative Breast Cancerbusinesswire.com · Jul 2020

Frequently asked questions

Who are Eikonoklastes Therapeutics's investors?
Eikonoklastes Therapeutics's investors include CincyTech, JobsOhio Ventures.
Where is Eikonoklastes Therapeutics headquartered?
Eikonoklastes Therapeutics is headquartered in Cincinnati, US.